Related Experiment Video
Updated: Jun 28, 2026
Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
Future treatment strategies of aggressive pituitary tumors
Steven W J Lamberts1, Leo J Hofland
1Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, 3015 CE Rotterdam, The Netherlands. s.w.j.lamberts@erasmusmc.nl
Abstract:
While surgery remains the first-line treatment of most aggressive pituitary adenomas, medical therapy is important as second-line or adjunctive therapy in a large proportion of patients. Dopamine agonists (DAs) are the best treatment for prolactinomas, but when DAs are not tolerated, new somatostatin receptor subtype 5 (SSTR(5)) inhibitors may offer an alternative in the future. Unfortunately, these are unlikely to be effective in DA-resistant prolactinomas. In acromegaly, the existing somatostatin analogs, octreotide and lanreotide, will remain the medical treatment of choice for the foreseeable future. There is an urgent need for medical therapies in Cushing's disease, and the SSTR(5) analogs could offer an effective treatment in a proportion of patients within the next few years. Finally, the medical management options for non-functioning pituitary adenomas are also very limited, and a new chimeric agent with activity towards dopamine receptors, SSTR(5) and SSTR(2) may help reduce adenoma recurrence in the future.
Insights
Medical therapies are crucial for aggressive pituitary adenomas when surgery isn't an option. Future treatments may include somatostatin receptor subtype 5 (SSTR(5)) inhibitors for Cushing's disease and chimeric agents for non-functioning adenomas.
Area of Science:
- Endocrinology
- Oncology
Background:
- Surgery is the primary treatment for aggressive pituitary adenomas.
- Medical therapy serves as a vital second-line or adjunctive treatment for many patients.
- Current medical options are limited for certain pituitary adenoma types.
Purpose of the Study:
- To review the current and future landscape of medical therapies for various pituitary adenomas.
- To identify unmet needs in the medical management of pituitary tumors.
- To explore the potential of novel therapeutic agents, including somatostatin receptor subtype 5 (SSTR(5)) inhibitors and chimeric agents.
Main Methods:
- Literature review of existing and emerging medical treatments for pituitary adenomas.
- Analysis of the efficacy and limitations of current therapies like dopamine agonists and somatostatin analogs.
- Discussion of potential new drug targets and agents.
Main Results:
- Dopamine agonists are effective for prolactinomas, with SSTR(5) inhibitors as a potential future alternative if not tolerated.
- Existing somatostatin analogs remain the standard for acromegaly.
- SSTR(5) analogs show promise for Cushing's disease, and chimeric agents may help prevent recurrence of non-functioning adenomas.
Conclusions:
- While surgery is primary, medical management is essential for aggressive pituitary adenomas.
- Novel therapies like SSTR(5) inhibitors and chimeric agents offer future hope for difficult-to-treat pituitary adenomas.
- Further research is needed to optimize medical treatment strategies for all pituitary adenoma subtypes.
